Publications + Posters

 |  SITC

November 2025

A Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TNG260 in combination with pembrolizumab in patients with STK11-mutated advanced solid tumors

Salman R. Punekar, et al.

 |  SITC

November 2025

TNG260, a novel small-molecule CoREST inhibitor, sensitizes STK11-mutant tumors to anti-PD-1 therapy

Leanne G. Ahronian, et al.

 |  SITC

November 2025

Inhibition of MGAT1 overcomes STK11-driven immune evasion in non-small cell lung cancer

Kiera M. Vassallo, et al.

 |  New England Biacore User Group Meeting

November 2025

Hit finding and assay enablement for MGAT1, a novel glycosyltransferase involved in cancer cell immune evasion

Kasia Handing

 |  New England Biacore User Group Meeting

November 2025

Use of SPR for Developing a HBS1L Molecular Glue Degrader

AJ Amor